Browsing by Author "Hamad, Anas"
Now showing items 1-7 of 7
-
Academic Entitlement Among Pharmacy Students in the Arab World: A Multi-National Exploratory Study
Hammoudi Halat, Dalal; Al-Jumaili, Ali Azeez; Ahmed, Kawther Khalid; Rahal, Mohamad; Hamad, Anas; Darwish, Rula M.; Alsous, Mervat M.; Thomas, Dixon; Bukhatwa, Salma; Khdour, Maher; Alkhudair, Nora; Al Balushi, Abdullah Ali; Khalifa, Sherief; Alsharif, Naser Z.... more authors ... less authors (2024 , Article)OBJECTIVE: The study's aim was to explore academic entitlement among pharmacy students in different pharmacy colleges in the Arab World and assess associated factors. METHODS: This study design was a cross-sectional survey. ... -
Cost savings and cost avoidance with the inpatient clinical pharmacist interventions in a tertiary cancer care hospital
Abushanab, Dina; Gulied, Amaal; Hamad, Anas; Abu-Tineh, Mohammad; Abdul Rouf, Palli V.; Al Hail, Moza; El-Kassem, Wessam; El Hajj, Maguy S.; Al-Badriyeh, Daoud... more authors ... less authors ( SAGE , 2023 , Article)Background: The economic benefit of the clinical pharmacist's role in ensuring the optimum use of medicines is potentially considerable, particularly when it comes to cancer management. We sought to evaluate the overall ... -
Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
Al-Ziftawi, Nour Hisham; Alam, Mohammed Fasihul; Elazzazy, Shereen; Shafie, Asrul Akmal; Hamad, Anas; Mohamed Ibrahim, Mohamed Izham... more authors ... less authors ( MDPI , 2022 , Article)Palbociclib and ribociclib are indicated in the first-line treatment of hormonal-receptor-positive HER-2 negative (HR+/HER-2 negative) advanced breast cancer. Despite their clinical benefit, they can increase healthcare ... -
Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
Laila, Shafei; Bashir, Shaima; Chan, Esther W.; Abushanab, Dina; Hamad, Anas; Al-Badriyeh, Daoud... more authors ... less authors ( Elsevier , 2024 , Article)PurposeSelinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the ... -
Home Cancer Care Research: A Bibliometric and Visualization Analysis (1990–2021)
Fhoula, Boutheina; Hadid, Majed; Elomri, Adel; Kerbache, Laoucine; Hamad, Anas; Al Thani, Mohammed Hamad J.; Al-Zoubi, Raed M.; Al-Ansari, Abdulla; Aboumarzouk, Omar M.; El Omri, Abdelfatteh... more authors ... less authors ( Multidisciplinary Digital Publishing Institute (MDPI) , 2022 , Article)Home cancer care research (HCCR) has accelerated, as considerable attention has been placed on reducing cancer-related health costs and enhancing cancer patients’ quality of life. Understanding the current status of HCCR ... -
Predictors of community pharmacists’ readiness to manage the effective and safe use of oral anticancer medicines in a developing setting
Dahmani, Sara; Cerbito, Emelith Florendo; Hamad, Anas; Yusuff, Kazeem Babatunde ( SAGE Publications Ltd , 2022 , Article)Background: There is a paucity of studies about the readiness of community pharmacists to manage the safe and effective use of oral anticancer medicines (OAMs) in developing settings. Objectives: Using the readiness component ... -
Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor.
Padmanabhan, Regina; Kheraldine, Hadeel; Gupta, Ishita; Meskin, Nader; Hamad, Anas; Vranic, Semir; Al Moustafa, Ala-Eddin... more authors ... less authors ( Frontiers Media , 2022 , Article)Immune checkpoint blockade (ICB)-based therapy is revolutionizing cancer treatment by fostering successful immune surveillance and effector cell responses against various types of cancers. However, patients with HER2+ ...